 |
Samsung Biologics. (Photo=Samsung Biologics) |
[Alpha Biz= Reporter Kim Jisun] Samsung Biologics announced on the 17th that it has signed a contract manufacturing organization (CMO) agreement with a U.S.-based pharmaceutical company.
The contract is valued at ₩111.2 billion, which represents 3.01% of Samsung Biologics' consolidated sales for the previous year. The agreement is set to last until October 2, 2030.
The identity of the partnering company will remain undisclosed until the contract's expiration due to confidentiality agreements. This follows Samsung Biologics' recent success in November, when it secured a ₩900 billion CMO deal with a European pharmaceutical firm.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
